Antiretroviral therapy has changed the natural history of HIV infection. However, antiretroviral therapy must be maintained for life. Its potential long-term adverse effects may interact synergistically with the ageing process, resulting in a higher incidence of comorbidities. The increasing number of non-antiretroviral drugs used to treat comorbidities may also place the patient at a higher risk of clinically meaningful interactions. Nowadays, efficacy is well demonstrated by all antiretroviral drugs compared with previous times. In fact a substantial number of HIV-infected patients from areas where antiretroviral therapy is widely available have achieved sustained suppression of plasma HIV replication. In contrast, the contributions of antiretroviral therapy to the development and progression of comorbidities and to the risk of potentially severe interactions have gained increasing importance as HIV-infected patients are getting older. More than half of HIV-infected patients aged ≥ 50 years have been reported to suffer from two or more concomitant comorbidities. In some of these patients, maintenance of antiretroviral therapy with combinations including NRTIs or PIs may be challenging (1). Data on ageing HIV patients under antiretroviral therapy are lacking.~RAL is considered one of the better-tolerated antiretroviral medications, due to limited side effects and few long-term safety concerns. Five-year clinical trial outcomes and clinical experience have demonstrated durable virologic suppression in both treatment-naïve and treatment-experienced patients, including patients with extensive antiretroviral history and documented antiretroviral resistance. Studies have also exhibited low adverse effect rates and reliable long-term safety lending to improved tolerance. Several trials have evaluated the reduction in adverse effects in patients switched from various antiretroviral agents to RAL. Treatment-naïve studies have demonstrated a lipid-neutral effect in patients on RAL-containing regimens. When transitioning patients from a ritonavir-boosted PI regimen, statistically significant decreases in total plasma cholesterol, low-density lipoprotein, and triglycerides were demonstrated. Given its negligible interaction with the cytochrome P450 system, RAL displays minimal drug-drug interactions, making it a good option for ageing patients on multiple medications (2).~Study Design~This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients. It is a phase IV study. 90 patients will be enrolled from the Department of Public Health and Infectious Diseases of Sapienza University of Rome. More than 4000 HIV patients are followed at this Department of Public Health and Infectious Diseases of Sapienza University of Rome. More than 50% of these patients are ≥ 50 years. From 10 to 12% are treated with a raltegravir based- regimen.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens we mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies.~Raltegravir initiation is equivalent to baseline.~All consecutive patients fulfilling the following inclusion criteria are considered eligible:~HIV-1 infected patients,~aged ≥ 60 years old~naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens,~experienced patients with virological suppression (HIV-1 RNA<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.~Data are collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months.~The following information will be extracted from the database of the Department:~demographics (age, sex, race)~smoking~risk factors for HIV infection~time from HIV-1 diagnosis (years)~history of AIDS diagnosis~hepatitis C virus (HCV) co-infection~hepatitis B virus (HBV) co-infection~presence of co-morbidities (including diabetes, hypertension, CVD, CKD, cancer, etc)~reasons for switching to raltegravir~time with HIV-1 RNA < 50 copies/mL before switch~BMI~Hematology (Hb, PLT)~Creatinine~eGFR (CKD-EPI formula)~Phosphorus~Calcium~AST~ALT~alkaline phosphatase~total, direct, indirect bilirubin~proteinuria~total, HDL-, LDL-cholesterol~triglycerides~glycemia~HIV-RNA~CD4+, CD8, CD4/CD8 ratio since the start of raltegravir~previous ART regimen and number of previous antiretroviral agents.~Follow-up will count from the date of start of raltegravir to VF/TF or last available visit, whichever first occurred~AEs were classified as mild/moderate, severe or life threatening, according to DAIDS Classification. AEs were considered unrelated to RAL, possibly related or related, according to physician criteria.~Safety data will be descriptive; no comparison data will be analyzed.~The primary endpoint will be the description of the proportion of participants with an HIV-1 viral load < 50 copies/mL.~The secondary endpoints will be:~Change from Baseline in CD4+ T-cell counts, CD8 cell counts, CD4/ CD8 ratio~Proportion of subjects with laboratory alterations~Proportion of patients with adverse events (AE), serious adverse events (SAE), also according to their severity
This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients. It is a phase IV study.~90 patients will be enrolled from the Department of Public Health and Infectious Diseases of Sapienza University of Rome.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered.